Advertisement
Screener

ARRIVENT BIOPHARMA, INC. (AVBP) Payments to Acquire Short-term Investments

2.2 / 5 stars · 7/16 Roast Me

ARRIVENT BIOPHARMA, INC. Payments to Acquire Short-term Investments

ARRIVENT BIOPHARMA, INC. (AVBP) reported Payments to Acquire Short-term Investments of $194.16 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-03.

Financial Statements › Cash Flow › Investing Activities

us-gaap:PaymentsToAcquireShortTermInvestments · last filed 2025-03-03

  • ARRIVENT BIOPHARMA, INC. payments to acquire short-term investments for the quarter ending 2023-12-31 was $0.00.
  • ARRIVENT BIOPHARMA, INC. payments to acquire short-term investments for the quarter ending 2023-09-30 was $0.00.
  • ARRIVENT BIOPHARMA, INC. payments to acquire short-term investments for fiscal 2024 was $194.16M, a 676.66% increase from fiscal 2023.
  • ARRIVENT BIOPHARMA, INC. payments to acquire short-term investments for fiscal 2023 was $25.00M.
Period endPayments to Acquire Short-term Investments 3 monthPayments to Acquire Short-term Investments 6 monthPayments to Acquire Short-term Investments 9 monthPayments to Acquire Short-term Investments 12 month
2024-12-31$194.16M
10-K · filed 2025-03-03
2023-12-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03
$0.00
derived: sum of 2 quarters · filed 2025-03-03
$25.00M
10-K · filed 2025-03-03
2023-09-30$0.00
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14
$25.00M
10-Q · filed 2024-11-14
2023-06-30$25.00M
10-Q · filed 2024-08-14

Similar stocks

Stock NameCountryMarket CapPE Ratio
Innoviva, Inc. (INVA)United States$1.493B4.62
Ultragenyx Pharmaceutical Inc. (RARE)United States$1.456B-5.62
OMEROS CORP (OMER)United States$1.456B5.50
ANAPTYSBIO, INC (ANAB)United States$1.546B-60.20
Kailera Therapeutics, Inc. (KLRA)United States$1.552B
Oric Pharmaceuticals, Inc. (ORIC)United States$1.367B-8.00
Syndax Pharmaceuticals Inc (SNDX)United States$1.606B-8.82
Rapport Therapeutics, Inc. (RAPP)United States$1.623B-14.56
Kardigan, Inc. (KARD)United States$1.346B
Stoke Therapeutics, Inc. (STOK)United States$1.630B-9.82